Literature DB >> 24306957

Expression of miRNAs and ZEB1 and ZEB2 correlates with histopathological grade in papillary urothelial tumors of the urinary bladder.

Heejeong Lee1, Sun-Young Jun, Youn-Soo Lee, Hee Jin Lee, Weon Sun Lee, Chul Soo Park.   

Abstract

Histopathological grading of papillary urothelial tumors (PUTs) of the urinary bladder is subjective and poorly reproducible. We investigated the relationship between the expression of frequently deregulated microRNAs (miRNAs) as well as their target genes (ZEB1/ZEB2) and bladder cancer histopathological grade in an attempt to find a miRNA that might allow more reliable grading of PUTs. We measured the expression levels of four miRNAs (miR-145, miR-205, miR-125b, and miR-200c) in 120 formalin-fixed, paraffin-embedded bladder tumor tissue samples using real-time PCR assays. ZEB1 and ZEB2 expression was assessed in the same bladder tissues by immunohistochemistry. MiR-205 distinguished low-grade papillary urothelial carcinoma (LG) from high-grade papillary urothelial carcinoma (HG), and miR-145 distinguished HG from infiltrating carcinoma (CA) with an area under the receiver operator characteristic curve (AUC) of 0.992 and 0.997, respectively (sensitivity/specificity of 95.8/96.7 % and 100/91.7 %, respectively; p < 0.05). The expression level of miR-125b was significantly lower in LG than in PUNLMP, with an AUC value of 0.870 (93.3 % sensitivity and 84.2 % specificity; p < 0.05). ZEB1 immunoreactivity was more frequently detected in HG than in LG (57 % vs 13 %, p < 0.01) and in HG than in CA (57 % vs 17 %, p < 0.01). ZEB2 immunoreactivity was more frequent in CA than in HG (83 % vs 54 %, p < 0.05). ZEB1/ZEB2 and miRNAs expression seems to reliably distinguish between different grades of PUTs of the urinary bladder. They might well serve as useful complementary diagnostic biomarkers for grading of papillary urothelial tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24306957     DOI: 10.1007/s00428-013-1518-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  27 in total

1.  The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading.

Authors:  Bas W G van Rhijn; Geert J L H van Leenders; Bert C M Ooms; Wim J Kirkels; Alexandre R Zlotta; Egbert R Boevé; Adriaan C Jöbsis; Theo H van der Kwast
Journal:  Eur Urol       Date:  2009-09-11       Impact factor: 20.096

2.  miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.

Authors:  Patricia Puerta-Gil; Rodrigo García-Baquero; Angela Y Jia; Sara Ocaña; Miguel Alvarez-Múgica; Jose L Alvarez-Ossorio; Carlos Cordon-Cardo; Fernando Cava; Marta Sánchez-Carbayo
Journal:  Am J Pathol       Date:  2012-03-15       Impact factor: 4.307

3.  MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3.

Authors:  Li Huang; Junhua Luo; Qingqing Cai; Qiuhui Pan; Hong Zeng; Zhenghui Guo; Wen Dong; Jian Huang; Tianxin Lin
Journal:  Int J Cancer       Date:  2011-04-15       Impact factor: 7.396

4.  Novel ZEB1 expression in bladder tumorigenesis.

Authors:  Patrick A Kenney; Matthew F Wszolek; Kimberly M Rieger-Christ; Brasil Silva Neto; Justin J Gould; Niall J Harty; Juan Miguel Mosquera; Ron Zeheb; Massimo Loda; Douglas S Darling; John A Libertino; Ian C Summerhayes
Journal:  BJU Int       Date:  2010-08-24       Impact factor: 5.588

5.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.

Authors:  Sun-Mi Park; Arti B Gaur; Ernst Lengyel; Marcus E Peter
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

6.  Distinct microRNA alterations characterize high- and low-grade bladder cancer.

Authors:  James W F Catto; Saiful Miah; Helen C Owen; Helen Bryant; Katie Myers; Ewa Dudziec; Stéphane Larré; Marta Milo; Ishtiaq Rehman; Derek J Rosario; Erica Di Martino; Margaret A Knowles; Mark Meuth; Adrian L Harris; Freddie C Hamdy
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

7.  A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer.

Authors:  Merle Hanke; Kai Hoefig; Hartmut Merz; Alfred C Feller; Ingo Kausch; Dieter Jocham; Jens M Warnecke; Georg Sczakiel
Journal:  Urol Oncol       Date:  2009-04-17       Impact factor: 3.498

8.  Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro.

Authors:  Lars Dyrskjøt; Marie S Ostenfeld; Jesper B Bramsen; Asli N Silahtaroglu; Philippe Lamy; Ramshanker Ramanathan; Niels Fristrup; Jens L Jensen; Claus L Andersen; Karsten Zieger; Sakari Kauppinen; Benedicte P Ulhøi; Jørgen Kjems; Michael Borre; Torben F Orntoft
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

9.  MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31.

Authors:  Srinivas Veerla; David Lindgren; Anders Kvist; Attila Frigyesi; Johan Staaf; Helena Persson; Fredrik Liedberg; Gunilla Chebil; Sigurdur Gudjonsson; Ake Borg; Wiking Månsson; Carlos Rovira; Mattias Höglund
Journal:  Int J Cancer       Date:  2009-05-01       Impact factor: 7.396

10.  Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder.

Authors:  Kutsal Yorukoglu; Burcin Tuna; Emel Dikicioglu; Ender Duzcan; Aydin Isisag; Sait Sen; Ugur Mungan; Ziya Kirkali
Journal:  Virchows Arch       Date:  2003-10-08       Impact factor: 4.064

View more
  18 in total

1.  Identification of novel gene targets and putative regulators of arsenic-associated DNA methylation in human urothelial cells and bladder cancer.

Authors:  Julia E Rager; Sloane K Tilley; Samantha E Tulenko; Lisa Smeester; Paul D Ray; Andrew Yosim; Jenna M Currier; María C Ishida; Maria Del Carmen González-Horta; Blanca Sánchez-Ramírez; Lourdes Ballinas-Casarrubias; Daniela S Gutiérrez-Torres; Zuzana Drobná; Luz M Del Razo; Gonzalo G García-Vargas; William Y Kim; Yi-Hui Zhou; Fred A Wright; Miroslav Stýblo; Rebecca C Fry
Journal:  Chem Res Toxicol       Date:  2015-06-03       Impact factor: 3.739

2.  Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.

Authors:  Christina Michailidi; Masamichi Hayashi; Sayantan Datta; Tanusree Sen; Kaitlyn Zenner; Oluwadamilola Oladeru; Mariana Brait; Evgeny Izumchenko; Alexander Baras; Christopher VandenBussche; Maria Argos; Trinity J Bivalacqua; Habibul Ahsan; Noah M Hahn; George J Netto; David Sidransky; Mohammad Obaidul Hoque
Journal:  Cancer Prev Res (Phila)       Date:  2015-01-13

Review 3.  MicroRNAs: Key Players in Bladder Cancer.

Authors:  Qi Li; Helei Wang; Hourong Peng; Qiuping Huang; Ting Huyan; Qingsheng Huang; Hui Yang; Junling Shi
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

4.  Long noncoding RNA SNHG22 increases ZEB1 expression via competitive binding with microRNA-429 to promote the malignant development of papillary thyroid cancer.

Authors:  Hong Gao; Xiaosong Sun; Hongdong Wang; Ying Zheng
Journal:  Cell Cycle       Date:  2020-04-19       Impact factor: 4.534

Review 5.  Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?

Authors:  Maria Schubert; Kerstin Junker; Joana Heinzelmann
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-12       Impact factor: 4.553

6.  TGFβ1 secreted by cancer-associated fibroblasts induces epithelial-mesenchymal transition of bladder cancer cells through lncRNA-ZEB2NAT.

Authors:  Junlong Zhuang; Qun Lu; Bing Shen; Xiaojing Huang; Lan Shen; Xi Zheng; Ruimin Huang; Jun Yan; Hongqian Guo
Journal:  Sci Rep       Date:  2015-07-08       Impact factor: 4.379

7.  miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer.

Authors:  Yan Hou; Junwen Zhen; Xiaodong Xu; Kun Zhen; Bin Zhu; Rui Pan; Chidong Zhao
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

8.  Evaluation of miR-141, miR-200c, miR-30b Expression and Clinicopathological Features of Bladder Cancer.

Authors:  Ali Mahdavinezhad; Seyed Habibollah Mousavi-Bahar; Jalal Poorolajal; Reza Yadegarazari; Mohammad Jafari; Nooshin Shabab; Massoud Saidijam
Journal:  Int J Mol Cell Med       Date:  2015

Review 9.  Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer.

Authors:  Alba Loras; Cristina Segovia; José Luis Ruiz-Cerdá
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

Review 10.  Transcription regulation of E-cadherin by zinc finger E-box binding homeobox proteins in solid tumors.

Authors:  Thian-Sze Wong; Wei Gao; Jimmy Yu-Wai Chan
Journal:  Biomed Res Int       Date:  2014-08-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.